LENZ Therapeutics, Inc. (LENZ)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$3.01-13.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · LENZ
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -41.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
LENZ — CEO transition
Dated 2026-10-28
CEO — Evert Schimmelpennink: The CEO is stepping down with a named internal successor (CFO) and a structured transition period, indicating an orderly succession rather than a sudden loss of leadership.
Why it matters: Q3 sales rose 50% from Q2, and management said momentum continued into Q4. Another strong quarter would support the launch story.
Supportive ifQ4 product sales exceed $3.9 million, 50% above Q3's $2.6 million.
Worry ifQ4 product sales are $2.6 million or less, showing no growth from Q3.
Why it matters: LENZ plans to cut projected 2027 costs by more than half. The final cost level will show whether the reorganization met that goal.
Supportive ifA 2027 report puts operating costs at $70 million to $75 million, not counting stock-based pay. This follows about $5 million in one-time charges.
Worry ifA 2027 report shows operating expenses above $75 million, not counting stock-based pay. Or it says the reorganization was not done in Q4 2026.
Why it matters: The two filings add to LENZ's overseas launch plan. Review decisions can show whether these markets move toward approval.
Supportive ifMalaysia or Vietnam grants marketing approval for VIZZ, or reports that its review is complete.
Worry ifEither health agency rejects the filing, asks for major new data, or the review is withdrawn.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$281 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $878 loss on $10,000 · 8.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,058 loss on $10,000 · 90.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.